PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ascendis

Insights+: EMA Marketing Authorization of New Drugs in November 2023

Insights+: EMA Marketing Authorization of New Drugs in November 2023

December 29, 2023

Ascendis Enters into Collaboration with Teijin Limited to Develop & Commercialize TransCon hGH, TransCon PTH, & TransCon CNP in Japan

Ascendis Enters into Collaboration with Teijin Limited to Develop & Commercialize TransCon hGH, TransCon PTH, & TransCon CNP in Ja...

November 29, 2023

Ascendis’ Yorvipath (palopegteriparatide) Receives the EC’s Approval for the Treatment of Chronic Hypoparathyroidism

Ascendis’ Yorvipath (palopegteriparatide) Receives the EC’s Approval for the Treatment of Chronic Hypoparathyroidism

November 21, 2023

Insights+: The US FDA New Drug Approvals in August 2021

Insights+: The US FDA New Drug Approvals in August 2021

September 16, 2021

PharmaShots Weekly Snapshots (August 23, 27, 2021)

PharmaShots Weekly Snapshots (August 23, 27, 2021)

August 27, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us